Abpro (NASDAQ:ABP) (NASDAQ:ABP) is a clinical-stage biotechnology company focused on the discovery and development of next-generation antibody therapeutics. Employing its proprietary ADAPT™ platform, Abpro engineers human antibodies with enhanced binding affinity, specificity and stability to address a wide range of disease targets. The company’s pipeline includes multiple mono- and bispecific candidates aimed at immuno-oncology checkpoints, autoimmune disorders and other serious conditions for which current therapies are insufficient.
Founded in 2016, Abpro has leveraged its core technology to build a diversified product portfolio that spans lead development through late preclinical stages. The ADAPT™ platform integrates state-of-the-art phage display, in silico modeling and high-throughput screening to optimize antibody binding and manufacturability. This approach enables rapid identification of high-potency molecules against validated and novel targets, reducing time-to-clinic for new programs. Alongside internal research efforts, Abpro has established strategic partnerships to advance selected candidates through clinical development.
Abpro maintains a global footprint with R&D operations in London and Beijing, an innovation hub in Boston and corporate offices in New York. This international presence supports collaborations with academic institutions and industry partners across Europe, North America and Asia. The company’s scientists and engineers work closely with external experts to refine target selection, preclinical modeling and translational research, ensuring that its antibody candidates are well positioned for regulatory review.
Under the leadership of seasoned executives with extensive experience in biologics and pharmaceutical development, Abpro has expanded from its initial laboratory team into a fully integrated preclinical organization. The management team combines expertise in antibody engineering, clinical operations and commercial strategy, aiming to accelerate the advancement of its pipeline into the clinic. As Abpro builds toward its first human studies, the company continues to strengthen its platform capabilities and deepen its target portfolio to address unmet medical needs worldwide.
